Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor

被引：42

作者：

Su, Qibin ^{[1
]}

Banks, Erica ^{[1
]}

Bebernitz, Geraldine ^{[1
]}

Bell, Kirsten ^{[1
]}

Borenstein, Cassandra F. ^{[1
]}

Chen, Huawei ^{[1
]}

Chuaqui, Claudio E. ^{[1
]}

Deng, Nanhua ^{[1
]}

Ferguson, Andrew D. ^{[2
,3
]}

Kawatkar, Sameer ^{[1
]}

Grimster, Neil P. ^{[1
]}

Ruston, Linette ^{[1
]}

Lyne, Paul D. ^{[1
]}

Read, Jon A. ^{[3
]}

Peng, Xianyou ^{[4
]}

Pei, Xiaohui ^{[4
]}

Fawell, Stephen ^{[1
]}

Tang, Zhanlei ^{[4
]}

Throner, Scott ^{[1
]}

Vasbinder, Melissa M. ^{[1
]}

Wang, Haoyu ^{[4
]}

Winter-Holt, Jon ^{[5
]}

Woessner, Richard ^{[1
]}

Wu, Allan ^{[2
]}

Yang, Wenzhan ^{[6
]}

Zinda, Michael ^{[1
]}

Kettle, Jason G. ^{[5
]}

机构：

[1] AstraZeneca R&D, Oncol R&D, Waltham, MA 02451 USA

[2] AstraZeneca R&D, R&D, Discovery Sci, Waltham, MA 02451 USA

[3] AstraZeneca R&D, R&D, Discovery Sci, Cambridge CB4 0WG, England

[4] Pharmaron Beijing Co Ltd, Beijing 100176, Peoples R China

[5] AstraZeneca R&D, Oncol R&D, Cambridge CB4 0WG, England

[6] R&D, Pharmaceut Sci, Early Product Dev, Boston, MA 02451 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2020年 / 63卷 / 09期

关键词：

PATENT LITERATURE 2013-2015; JAK-FAMILY KINASES; RHEUMATOID-ARTHRITIS; INADEQUATE RESPONSE; STAT3; ACTIVATION; PATHWAY; CANCER; IDENTIFICATION; PROLIFERATION; PEFICITINIB;

D O I：

10.1021/acs.jmedchem.9b01392

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

JAK1, JAK2, JAK3, and TYK2 belong to the JAK (Janus kinase) family. They play critical roles in cytokine signaling. Constitutive activation of JAK/STAT pathways is associated with a wide variety of diseases. Particularly, pSTAT3 is observed in response to the treatment with inhibitors of oncogenic signaling pathways such as EGFR, MAPK, and AKT and is associated with resistance or poorer response to agents targeting these pathways. Among the JAK family kinases, JAK1 has been shown to be the primary driver of STAT3 phosphorylation and signaling; therefore, selective JAK1 inhibition can be a viable means to overcome such treatment resistances. Herein, an account of the medicinal chemistry optimization from the promiscuous kinase screening hit 3 to the candidate drug 21 (AZD4205), a highly selective JAK1 kinase inhibitor, is reported. Compound 21 has good preclinical pharmacokinetics. Compound 21 displayed an enhanced antitumor activity in combination with an approved EGFR inhibitor, osimertinib, in a preclinical non-small-cell lung cancer (NSCLC) xenograft NCI-H1975 model.

引用

页码：4517 / 4527

页数：11

共 50 条

[21] Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor [J].

Ebiike, Hirosato ;

Taka, Naoki ;

Matsushita, Masayuki ;

Ohmori, Masayuki ;

Takami, Kyoko ;

Hyohdoh, Ikumi ;

Kohchi, Masami ;

Hayase, Tadakatsu ;

Nishii, Hiroki ;

Morikami, Kenji ;

Nakanishi, Yoshito ;

Akiyama, Nukinori ;

Shindoh, Hidetoshi ;

Ishii, Nobuya ;

Isobe, Takehito ;

Matsuoka, Hiroharu .

JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (23) :10586-10600

[22] 2-(1H-Pyrazol-4-yl) acetic acids as CRTh2 antagonists [J].

Andres, Miriam ;

Bravo, Monica ;

Antonia Buil, Maria ;

Calbet, Marta ;

Castro, Jordi ;

Domenech, Teresa ;

Eichhorn, Peter ;

Ferrer, Manel ;

Gomez, Elena ;

Lehner, Martin D. ;

Moreno, Imma ;

Roberts, Richard S. ;

Sevilla, Sara .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (11) :3349-3353

[23] Novel N-Substituted 2-(2-(Adamantan-1-yl)-1H-Indol-3-yl)-2-Oxoacetamide Derivatives: Synthesis and Biological Evaluation [J].

Hu, Hong-Yu ;

Yu, Xu-Dong ;

Wang, Fei ;

Lin, Chun-Rong ;

Zeng, Jin-Zhang ;

Qiu, Ying-Kun ;

Fang, Mei-Juan ;

Wu, Zhen .

MOLECULES, 2016, 21 (05)

[24] Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]midazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity [J].

Ndubaku, Chudi O. ;

Heffron, Timothy P. ;

Staben, Steven T. ;

Baumgardner, Matthew ;

Blaquiere, Nicole ;

Bradley, Erin ;

Bull, Richard ;

Do, Steven ;

Dotson, Jennafer ;

Dudley, Danette ;

Edgar, Kyle A. ;

Friedman, Lori S. ;

Goldsmith, Richard ;

Heald, Robert A. ;

Kolesnikov, Aleksandr ;

Lee, Leslie ;

Lewis, Cristina ;

Nannini, Michelle ;

Nonomiya, Jim ;

Pang, Jodie ;

Price, Steve ;

Prior, Wei Wei ;

Salphati, Laurent ;

Sideris, Steve ;

Wallin, Jeffery J. ;

Wang, Lan ;

Wei, BinQing ;

Sampath, Deepak ;

Olivero, Alan G. .

JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (11) :4597-4610

[25] Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]-propanamides as selective agonists of human formyl-peptide receptor 2 [J].

Lacivita, Enza ;

Schepetkin, Igor A. ;

Stama, Madia L. ;

Kirpotina, Liliya N. ;

Colabufo, Nicola A. ;

Perrone, Roberto ;

Khlebnikov, Andrei I. ;

Quinn, Mark T. ;

Leopoldo, Marcello .

BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (14) :3913-3924

[26] 5-(2-Amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro- pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors [J].

Caruso, Michele ;

Valsasina, Barbara ;

Ballinari, Dario ;

Bertrand, Jay ;

Brasca, Maria Gabriella ;

Caldarelli, Marina ;

Cappella, Paolo ;

Fiorentini, Francesco ;

Gianellini, Laura M. ;

Scolaro, Alessandra ;

Beria, Italo .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (01) :96-101

[27] Synthesis, Structure and Biological Activity of 2-[2-(4-Fluorobenzylidene)hydrazinyl]-4-(1-methyl-1H-indol-3-yl)thieno[3,2-d]pyrimidine [J].

Shi Jian-Tao ;

Gong Yi-Lin ;

Li Jun ;

Wang Yang ;

Chen Ye ;

Ding Shi ;

Liu Ju .

CHINESE JOURNAL OF STRUCTURAL CHEMISTRY, 2019, 38 (09) :1530-1536

[28] Synthesis, acetylcholinesterase, butyrylcholinesterase and tyrosinase inhibition, and antioxidant studies of 2-[2-(substituted-benzyl)-4(7)-phenyl-1H-benzimidazol-1-yl] acetohydrazides and methyl 2-[2-(substituted-benzyl)-4(7)-phenyl-1H-benzimidazol-1-yl] acetates [J].

Gumus, M. K. ;

Dogan, I. S. ;

Barut, B. ;

Ozel, A. ;

Kahveci, B. .

BULGARIAN CHEMICAL COMMUNICATIONS, 2017, 49 :107-114

[29] Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors [J].

Wang, Xing-Rong ;

Wang, Shuai ;

Li, Wen-Bo ;

Xu, Kai-Yan ;

Qiao, Xue-Peng ;

Jing, Xue-Li ;

Wang, Zi-Xiao ;

Yang, Chang-jiang ;

Chen, Shi-Wu .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 213

[30] Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus [J].

Park, Kaapjoo ;

Lee, Byoung Moon ;

Hyun, Kwan Hoon ;

Lee, Dong Hoon ;

Choi, Hyun Ho ;

Kim, Hyunmi ;

Chong, Wonee ;

Kim, Kyeong Bae ;

Nam, Su Youn .

BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (07) :2280-2293

← 1 2 3 4 5 →